BRIEF — Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84

Oct 12 (Reuters) — Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals - Pasatru Shows Sustained Efficacy And Consistent Safety Profile From Weeks 56 To 84 Regeneron Pharmaceuticals - Pasatru Maintains Well-tolerated Safety Profile Through Week 84 Source text:... Further company coverage: REGN.O (Reuters.Briefs@thomsonreuters.com;)